

# **Alzheimer Disease**

## **New Drugs, Markets & Companies**

**A Jain PharmaBiotech Report**

# **Alzheimer Disease**

## **New Drugs, Markets & Companies**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**June 2018**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is CEO and consultant at Jain PharmaBiotech. Prof. Jain's 474 publications including 28 books (5 as editor + 23 as author) and 50 special reports, which cover important areas in biotechnology, cell/gene therapies and biopharmaceuticals. Recent books relevant to the nervous system include "Handbook of Neuroprotection" (Springer, 2011) and "Applications of Biotechnology in Neurology" (Springer 2013). In addition to the above, he has edited "Applied Neurogenomics" (Springer 2015).

**June 2018 (first edition in 2003)**  
**Copyright © 2018 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:       +4161-6924461**  
**Email:            info@pharmabiotech.ch**  
**Web site:         http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>0. Executive Summary .....</b>	<b>17</b>
<b>1. Clinical Features, Epidemiology and Pathology .....</b>	<b>19</b>
<b>Introduction.....</b>	<b>19</b>
<b>Historical aspects.....</b>	<b>19</b>
<b>Clinical features of Alzheimer disease.....</b>	<b>20</b>
Seven stages of Alzheimer disease .....	22
AD as a terminal illness .....	24
Detection of AD in the preclinical phase .....	24
Differentiation of AD from other dementias .....	24
Differentiation of AD from non-dementing disorders .....	25
Cerebral insufficiency and AD .....	26
Memory deficits and preclinical AD .....	26
Sleep disorders and AD.....	27
<i>Circadian rhythms and sleep in AD .....</i>	<i>27</i>
Mild cognitive impairment .....	28
Evolution of diagnostic criteria of AD .....	29
Revised criteria for the clinical diagnosis of AD .....	31
<b>Epidemiology .....</b>	<b>32</b>
Epidemiology of aging .....	32
Epidemiology of dementia .....	34
Epidemiology of AD.....	34
<i>Prevalence of AD according to age .....</i>	<i>35</i>
<i>Mortality in AD.....</i>	<i>35</i>
<b>Pathophysiology of AD .....</b>	<b>35</b>
Cerebral atrophy and neuronal loss .....	35
Neuritic plaques and neurofibrillary tangles .....	36
See-through 3D imaging of the AD brain.....	36
Sp proteins as markers of neuronal death in AD.....	37
Role of tau in the pathogenesis of AD .....	37
RNA-binding proteins and AD .....	39
Amyloid precursor protein .....	40
<i>APP intracellular domain .....</i>	<i>40</i>
<i>Relation of APP mutations to CNS disorders.....</i>	<i>40</i>
<i>Relation of APP to A<math>\beta</math> deposits and pathogenesis of AD .....</i>	<i>41</i>
<i>Role of neprilysin in A<math>\beta</math> degradation.....</i>	<i>42</i>
<i>Role of secretases in amyloid cascade.....</i>	<i>42</i>
<i>Role of exosomal proteins .....</i>	<i>44</i>
<i>Role of nicastrin .....</i>	<i>44</i>
Neurotoxicity of A $\beta$ deposits .....	44
<i>A<math>\beta</math> production and clearance.....</i>	<i>46</i>
<i>A<math>\beta</math>-mediated synaptic and cognitive deficits .....</i>	<i>47</i>
<i>Dysfunction of TGF-<math>\beta</math> signaling accelerates A<math>\beta</math> deposition .....</i>	<i>47</i>
<i>Interaction of A<math>\beta</math> with neuron-specific Na<math>^{+}</math>/K<math>^{+}</math>-ATPase <math>\alpha</math>3 subunit .....</i>	<i>47</i>
<i>Relation of A<math>\beta</math> deposits to synaptic activity.....</i>	<i>48</i>
<i>Role of TMP21 in presenilin complexes and A<math>\beta</math> formation.....</i>	<i>48</i>
<i>Role of A<math>\beta</math> dimers in the pathogenesis of AD.....</i>	<i>49</i>
<i>Role of dsDNA breaks in neurodegeneration due to A<math>\beta</math>.....</i>	<i>49</i>
<i>Structure–neurotoxicity relationships of A<math>\beta</math> oligomers.....</i>	<i>49</i>
<i>Sequence of events in neurotoxicity of A<math>\beta</math> .....</i>	<i>50</i>
Impairment of mitochondrial energy metabolism .....	51
<i>A<math>\beta</math>-binding alcohol dehydrogenase links AD to mitochondrial toxicity .....</i>	<i>51</i>
Neural thread protein .....	52
Loss of synaptic proteins .....	52
<i>AD and Down syndrome.....</i>	<i>52</i>
<i>Overlapping pathologies of AD and Parkinson disease .....</i>	<i>53</i>
<i>AD and age-related macular degeneration.....</i>	<i>53</i>
<i>Myelin hypothesis of AD.....</i>	<i>53</i>
<i>Blood-brain barrier in AD .....</i>	<i>54</i>
<i>Blood vessel damage in AD .....</i>	<i>55</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>55</i>
Factors in pathogenesis of AD.....	56
<i>Astrocytes and AD.....</i>	<i>56</i>
<i>Axonal transport failure in AD .....</i>	<i>56</i>
<i>Cell-cycle hypothesis .....</i>	<i>57</i>
<i>Chronic heart failure link with AD .....</i>	<i>57</i>
<i>Creatine and AD.....</i>	<i>57</i>
<i>Disturbances in brain metabolism in early AD .....</i>	<i>57</i>

<i>Disturbances of interaction of nervous system proteins</i> .....	58
<i>Disturbance of lipid metabolism in the brain</i> .....	58
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD</i> .....	59
<i>Dopamine and AD</i> .....	59
<i>Functioning role of genes in pathomechanism of AD</i> .....	59
<i>Gonadotrophins and AD</i> .....	59
<i>Glutamate transport dysfunction in AD</i> .....	60
<i>Herpes simplex virus type 1 and AD</i> .....	61
<i>Innate immune system and AD</i> .....	61
<i>Insulin, diabetes and AD</i> .....	62
<i>Mechanisms underlying cognitive deficits in AD</i> .....	63
<i>Microglia and AD</i> .....	64
<i>Monoamine oxidase and AD</i> .....	64
<i>Neuroinflammation and AD</i> .....	64
<i>Neurotransmitter deficits</i> .....	66
<i>Neurotrophic factors</i> .....	66
<i>NF-<math>\kappa</math>B signaling and the pathogenesis of neurodegeneration</i> .....	67
<i>Nitric oxide and AD</i> .....	67
<i>Nogo receptor pathway</i> .....	70
<i>Oxidative stress and AD</i> .....	70
<i>Prostaglandins and AD</i> .....	72
<i>Quinolinic acid and AD</i> .....	72
<i>Retromer deficiency</i> .....	72
<i>Serotonin and AD</i> .....	73
Spread of neurodegeneration.....	73
<i>Synaptic failure in AD</i> .....	73
<i>Transmission of AD</i> .....	74
<i>Ubiquitin-proteasome system in pathogenesis of AD</i> .....	75
Risk factors in the etiology of AD.....	75
<i>Aging and developmental abnormalities of the cholinergic system</i> .....	76
<i>Cholesterol, dietary lipids, and A<math>\beta</math></i> .....	76
<i>Epigenetic link between aging and AD</i> .....	77
<i>Exposure to magnetic fields</i> .....	78
<i>Family history of AD</i> .....	78
<i>Homocysteine and AD</i> .....	78
<i>Hypertension and AD</i> .....	79
<i>Level of education/type of job and risk of AD</i> .....	79
<i>Metals and AD</i> .....	80
<i>Obesity</i> .....	81
<i>Proneness to psychological distress and risk of AD</i> .....	82
<i>Reduced muscle strength</i> .....	82
<i>Sleep deprivation</i> .....	82
<i>Traumatic brain injury and AD</i> .....	83
<i>Vascular risk factors for AD</i> .....	84
<i>Vitamin B12 and folate</i> .....	85
AD versus non-dementing changes in the aging brain.....	85
AD and cognitive impairment with aging.....	86
Pathomechanism of memory impairment and AD.....	86
Concluding remarks on pathophysiology of AD.....	87
<b>Genetics of AD</b> .....	<b>88</b>
<i>Familial AD</i> .....	89
<i>Molecular genetics of familial AD</i> .....	89
<i>Presenilins and calcium channel pathogenesis of familial AD</i> .....	90
<i>Presenilin-1 mutations and familial AD</i> .....	90
<i>Late onset AD</i> .....	91
<b>Genomics of AD</b> .....	<b>91</b>
Introduction to genomics.....	91
Genes associated with Alzheimer disease.....	92
<i>AlzGene database</i> .....	93
<i>ApoE gene</i> .....	93
<i>ApoE genotype and nitric oxide</i> .....	94
<i>ApoE genotype modulates AD phenotype</i> .....	95
<i>APOE genotype and age-related myelin breakdown</i> .....	95
<i>ApoE receptor interaction with NMDA receptor</i> .....	96
<i>ApoE and ApoER2</i> .....	96
<i>ApoE receptor LR11 as regulator of A<math>\beta</math></i> .....	96
<i>Arctic mutation</i> .....	97
<i>BCHE gene</i> .....	97
<i>BRCA1 and AD</i> .....	97
<i>CALHM1 polymorphism and AD</i> .....	97
<i>CLU, CRI and PICALM</i> .....	98

<i>CYP46 and risk for AD</i> .....	98
<i>DAPK1 gene variants and AD</i> .....	99
Genetic variants associated with early-onset AD .....	99
Genetic variants associated with late-onset AD .....	99
<i>ApoE polymorphisms associated with LOAD</i> .....	99
<i>Copy number variation (CNV) in LOAD</i> .....	100
<i>LRRTM3 as a candidate gene for AD</i> .....	100
<i>MTHFD1L gene variant associated with AD</i> .....	100
<i>Mutation in APP gene with protective effect against AD</i> .....	101
<i>OGG1 mutations associated with AD</i> .....	101
<i>SORL1 gene in AD</i> .....	101
<i>TOMM40 gene and risk of AD</i> .....	101
<i>TREM2 variants in AD</i> .....	102
International Genomics of Alzheimer's Project .....	102
Sequencing in Alzheimer disease .....	103
Molecular neuropathology .....	104
Role of microRNAs in AD .....	105
DNA methylation in AD .....	106
AD as a polygenic disorder .....	106
<b>Proteomics of AD</b> .....	<b>107</b>
Introduction .....	107
Application of proteomic technologies to study AD.....	107
Protein misfolding in AD.....	109
Common denominators of AD and prion diseases .....	110

## **2. Diagnostic Procedures for Alzheimer Disease ..... 112**

<b>Importance of the diagnosis of Alzheimer disease</b> .....	<b>112</b>
<b>Methods of diagnosis of AD</b> .....	<b>112</b>
Self-administered olfactory test .....	113
Neuropsychological testing.....	113
Assessment and evaluation .....	114
<i>7-minute screen</i> .....	114
<i>15-point risk index</i> .....	115
<i>Activities of Daily Living</i> .....	115
<i>Alzheimer Disease Cooperative Study</i> .....	115
<i>CDR-SOB score</i> .....	115
<i>Clinician's Interview-Based Impression of Change</i> .....	116
<i>DETECT™ System</i> .....	116
<i>Measurement of aggregation in anterior segment of the eye</i> .....	116
<i>Resource Utilization in Dementia Battery</i> .....	116
<i>SymptomGuide™</i> .....	116
Electrophysiology .....	117
<i>Quantitative EEG for investigation of early AD</i> .....	117
<i>EEG-based bispectral index</i> .....	117
<i>Event-related potentials</i> .....	117
<i>Correlation of electrical activity of the brain with cognition</i> .....	118
Early detection of cataract associated with AD .....	118
Retinal imaging to detect A $\beta$ deposits .....	118
Laboratory methods for diagnosis of AD.....	119
Monitoring of synthesis and clearance rates of A $\beta$ in the CSF .....	119
Molecular diagnostics for AD.....	120
<i>Genetic tests for AD</i> .....	121
<i>ApoE genotyping</i> .....	122
<i>Gene expression patterns in AD</i> .....	122
<i>Monoclonal antibody-based in vitro diagnosis of AD from brain tissues</i> .....	122
<i>Multi-tissue RNA signature of aging as diagnostic for AD</i> .....	122
Biomarkers of AD.....	123
The ideal biomarker for AD.....	125
CSF biomarkers of AD.....	125
<i>CSF sulfatide as a biomarker for AD</i> .....	125
<i>Glycerophosphocholine as CSF biomarker in AD</i> .....	126
<i>Protein biomarkers of AD in CSF</i> .....	126
<i>Tau proteins in CSF</i> .....	128
<i>Tests for the detection of A<math>\beta</math> in CSF</i> .....	128
<i>Tests combining CSF tau and A<math>\beta</math></i> .....	129
<i>Concluding remarks about CSF biomarkers of AD</i> .....	129
Urine tests for AD .....	130
Blood tests for AD .....	130
<i>A serum protein-based algorithm for the detection of AD</i> .....	130
<i><math>\alpha</math>2-macroglobulin as a biomarker of preclinical and early AD</i> .....	130
<i>Blood A<math>\beta</math> level as biomarker of AD</i> .....	131

<i>Blood test for AD based on heme oxygenase-1</i> .....	132
<i>Blood test for AD based on RNA hybridization</i> .....	132
<i>GSK-3 elevation in white blood cells</i> .....	132
<i>Lipid biomarkers for preclinical detection of AD</i> .....	132
<i>Lymphocyte Proliferation Test</i> .....	133
<i>Metabolomic biomarker profiling</i> .....	133
<i>MGAT3 as biomarker for prognosis of AD</i> .....	133
<i>MicroRNA-based test for AD</i> .....	134
<i>Protein kinase C in red blood cells</i> .....	134
<i>Sphingolipids</i> .....	134
<i>Tests based on protein biomarkers in blood</i> .....	134
Skin test for early detection of AD .....	135
Saliva-based tests for AD .....	135
<i>Saliva A<math>\beta</math>42 level as a biomarker of AD</i> .....	135
Smell identification test .....	136
Nanotechnology to measure A $\beta$ -derived diffusible ligands .....	136
Simultaneous measurement of several biomarkers for AD .....	136
Nutritional biomarkers in plasma of AD patients .....	137
Plasma biomarkers of drug response in AD .....	137
Biomarkers of disease modifying therapies for AD .....	138
Concluding remarks about biomarkers for AD .....	138
<b>Imaging in AD</b> .....	<b>138</b>
Computed tomography .....	139
Magnetic resonance imaging .....	139
<i>Arterial spin labeling with MRI</i> .....	139
<i>Magnetic resonance microscopy</i> .....	140
<i>Magnetic resonance spectroscopy</i> .....	140
Single photon emission computed tomography and modifications .....	141
Positron emission tomography .....	141
In vivo imaging of A $\beta$ deposits by PET .....	143
<i>Pittsburgh compound B and PET</i> .....	143
<i>Florbetapir-PET</i> .....	144
<i>Florbetaben-PET</i> .....	145
<i>Flutemetamol-PET</i> .....	146
<i>Future prospects of the PET imaging in AD</i> .....	146
In vivo detection of A $\beta$ plaques by MRI .....	146
Imaging agents for A $\beta$ and neurofibrillary tangles .....	147
Hyperspectral Raman imaging of neuritic plaques in AD .....	147
Targeting of a chemokine receptor as biomarker for brain imaging .....	148
Radioiodinated clioquinol as a biomarker for A $\beta$ .....	148
In vivo imaging of tau by PET .....	149
Imaging neuroinflammation in AD by PET .....	149
Preclinical diagnosis of AD .....	149
<i>Correlation of imaging with CSF biomarkers for early detection of AD</i> .....	150
Meta-analysis of literature on imaging in AD .....	150
Alzheimer Disease Neuroimaging Initiative .....	150
Computer aided diagnosis systems for AD based on imaging data .....	151
Concluding remarks on imaging for diagnosis of AD .....	152
<b>Diagnosis of MCI and prediction of AD</b> .....	<b>152</b>
Diagnosis of MCI .....	152
<i>Computer-Administered Neuropsychological screen for MCI</i> .....	153
<i>Infrared eye-tracking technology to detect MCI</i> .....	153
<i>MRI for detection of MCI</i> .....	153
<i>PET for detection of MCI</i> .....	153
<i>Role of APOE genotype in early MCI</i> .....	154
Presymptomatic detection of AD .....	154
<i>Biomarker changes in autosomal dominantly inherited AD</i> .....	155
<i>Blood test for preclinical diagnosis of AD</i> .....	155
<i>Gait analysis during cognitive tasks</i> .....	156
PredictAD project .....	156
Prediction of AD in patients with MCI .....	156
<i>Biochemical biomarkers in CSF for prediction of AD</i> .....	156
<i>Clinical and biochemical biomarkers for profiling prodromal AD</i> .....	157
<i>Combination of MMSE and a memory test for prediction of AD</i> .....	157
<i>Plasma protein biomarkers of conversion of MCI to AD</i> .....	157
<i>Structural MRI biomarkers for prediction of AD</i> .....	157
<i>Magnetoencephalography for detection of MCI and AD</i> .....	158
<i>MRI-based index to measure the severity of AD in MCI</i> .....	158
<i>Concluding remarks about prediction of AD in MCI</i> .....	159
<b>Criteria for diagnosis of AD</b> .....	<b>159</b>
Role of biomarkers in diagnosis of AD dementia .....	160

<b>Ethical aspects of diagnostics for AD .....</b>	<b>161</b>
Genetic testing for AD .....	161
Ethical issues of brain imaging in AD .....	162
Monitoring of treatment of AD .....	162
<i>Monitoring treatment of mixed AD and vascular dementia .....</i>	<i>163</i>
<b>Companies involved in diagnosis of AD .....</b>	<b>163</b>
<b>3. Management of Alzheimer Disease .....</b>	<b>166</b>
<b>Introduction.....</b>	<b>166</b>
<b>Cholinergic approaches.....</b>	<b>166</b>
Mechanism of action of cholinesterase inhibitors .....	167
Choline and lecithin .....	168
Donepezil.....	169
Rivastigmine .....	170
Galantamine.....	171
Duration of treatment with ChE inhibitors.....	172
<b>Comparative studies of ChE inhibitors .....</b>	<b>172</b>
Donepezil versus rivastigmine .....	172
Donepezil versus galantamine .....	173
Combination of cholinesterase inhibitors and a cholinergic precursor .....	173
An assessment and future prospects of anticholinergic therapies.....	174
<b>Neuroprotection in Alzheimer's disease .....</b>	<b>174</b>
Memantine .....	175
<i>Pharmacology of memantine .....</i>	<i>175</i>
<i>Clinical trials of memantine .....</i>	<i>176</i>
<i>Combination of memantine with ChE inhibitors .....</i>	<i>178</i>
Monoamine oxidase inhibitors.....	179
<i>Selegiline.....</i>	<i>179</i>
Synaptoprotection in AD .....	179
<b>Drugs for noncognitive symptoms in AD .....</b>	<b>179</b>
Antidepressants .....	180
Antipsychotics .....	180
ChE inhibitors for behavioral and psychological disorders in AD.....	180
Concluding remarks and other drugs for agitation in AD.....	181
Sensory stimulation.....	182
<b>Non-pharmacological treatments of AD .....</b>	<b>182</b>
Cerebrospinal fluid shunting .....	182
Deep brain stimulation.....	183
Exposure of the brain to electromagnetic fields for treatment of AD.....	183
<i>Application of electrical fields for improvement of cerebral function .....</i>	<i>184</i>
<i>High-frequency electromagnetic field treatment of AD .....</i>	<i>184</i>
<i>Transcranial magnetic stimulation .....</i>	<i>184</i>
Mental training for management of memory loss in AD .....	185
Microchip-based hippocampal prosthesis for AD .....	185
Omental transposition .....	185
Photo-induced inhibition of A $\beta$ accumulation in AD .....	186
Scanning ultrasound for removal of A $\beta$ .....	186
Vagal nerve stimulation .....	186
<b>Nutritional therapies for AD .....</b>	<b>187</b>
Axona.....	187
Cocktail of dietary supplements for AD .....	187
Docosahexaenoic acid.....	188
Magnesium .....	189
Nicotinamide for the treatment of AD .....	189
Omega-3 fatty acids.....	190
<b>Preventing decline of mental function with aging and dementia.....</b>	<b>191</b>
<b>Prevention of Alzheimer disease.....</b>	<b>191</b>
<i>Mental training .....</i>	<i>193</i>
<i>Physical exercise.....</i>	<i>193</i>
<i>Higher level of conscientiousness and decreased risk of AD .....</i>	<i>194</i>
Nutritional factors in prevention of AD and MCI.....	194
<i>Black and green teas.....</i>	<i>194</i>
<i>Caffeine.....</i>	<i>195</i>
<i>Caloric restriction.....</i>	<i>195</i>
<i>Cinnamon .....</i>	<i>195</i>
<i>Cocoa flavonol consumption .....</i>	<i>196</i>
<i>Grapes and red wine .....</i>	<i>196</i>
<i>Vitamin D and docosahexaenoic acid .....</i>	<i>197</i>
Drugs to prevent Alzheimer disease .....	197
Preimplantation genetic diagnosis of inherited Alzheimer disease .....	198
Presymptomatic detection of AD .....	198



<b>Management of mild cognitive impairment .....</b>	<b>198</b>
Slowing the progression of MCI to AD .....	198
<b>Management of Down syndrome.....</b>	<b>199</b>
<b>Guidelines for use of anti-dementia drugs in clinical practice .....</b>	<b>200</b>
Donepezil and/or memantine .....	201
<b>General care of the Alzheimer disease patients .....</b>	<b>201</b>
<b>Strategies for the management of Alzheimer disease .....</b>	<b>202</b>
<b>4. Research in Alzheimer Disease .....</b>	<b>203</b>
<b>Introduction.....</b>	<b>203</b>
<b>Animal models of Alzheimer disease .....</b>	<b>203</b>
Lesional models .....	203
<i>Cerebroventricular injection of A<math>\beta</math> in rats .....</i>	<i>203</i>
<i>Lentiviral vector-based models of amyloid pathology .....</i>	<i>204</i>
<i>AAV-mediated gene transfer to increase hippocampal A<math>\beta</math> .....</i>	<i>204</i>
Transgenic mouse models .....	204
<i>Quantitative assessment of amyloid load in transgenic models.....</i>	<i>205</i>
<i>In vivo magnetic resonance microimaging in transgenic models of AD .....</i>	<i>206</i>
<i>Transgenic model of AD with suppression of A<math>\beta</math> production.....</i>	<i>206</i>
<i>Transgenic AD11 anti-NGF mice.....</i>	<i>206</i>
<i>Genetically altered mice with deficiency of vesicular ACh transporter .....</i>	<i>207</i>
<i>Limitations of mouse models of Alzheimer disease .....</i>	<i>207</i>
<i>Improved mouse models of AD expressing human genes .....</i>	<i>208</i>
Cholesterol-fed rabbits as models for AD.....	208
Canine dementia as model for AD .....	208
Zebrafish model for AD .....	209
Transgenic invertebrate models of Alzheimer disease .....	210
<i>Drosophila model of AD .....</i>	<i>210</i>
<i>Caenorhabditis elegans Alzheimer disease model .....</i>	<i>210</i>
Correlation of studies in animal models and human clinical trials.....	211
<b>Cell systems for AD research .....</b>	<b>212</b>
In vitro neuronal cell Lines .....	212
Single-gene expression system for use in cell culture .....	212
Stem cells for testing efficacy of AD drugs.....	212
Transgenic cells .....	213
In silico models.....	213
<b>Estimation of progression rates of Alzheimer disease.....</b>	<b>214</b>
<b>Clinical trial methods in Alzheimer disease .....</b>	<b>214</b>
Molecular imaging as a guide to drug development .....	215
Use of MRI and PET in clinical trials .....	215
Cognitive-function assessment in clinical trials.....	216
Clinical trials in mild cognitive impairment.....	216
<b>Research in AD as a basis for future therapies.....</b>	<b>217</b>
Use of microarrays for studying pathogenesis of AD .....	217
Computational brain mapping in AD .....	217
Study of neurogenesis in AD.....	217
Study of 3D structure of A $\beta$ .....	217
Solid-state NMR to study precursors of A $\beta$ .....	218
<b>Research in Alzheimer disease at academic centers .....</b>	<b>218</b>
Role of NIH in AD research.....	218
NIH Clinical Trials Database for AD.....	218
Alzheimer Research Consortium.....	218
The National Institute on Aging and AD research.....	219
<b>5. Drug Discovery &amp; Development for Alzheimer Disease .....</b>	<b>221</b>
<b>Introduction.....</b>	<b>221</b>
<b>Categories of drugs in development for AD .....</b>	<b>221</b>
<b>Memory-enhancing drugs .....</b>	<b>223</b>
Enhancing memory by drugs that block eIF2 $\alpha$ phosphorylation .....	223
<b>Drugs based on cholinergic approaches .....</b>	<b>223</b>
AP2238.....	224
Butyrylcholinesterase inhibitors .....	224
Donepezil-tacrine hybrids.....	224
Drugs modulating gamma-aminobutyric acid receptors .....	225
Ganstigmina .....	225
Methanesulfonyl fluoride .....	225
Muscarinic receptor modulators .....	226
<i>Muscarinic M1 agonists .....</i>	<i>226</i>
<i>Muscarinic M2 antagonists.....</i>	<i>227</i>
Nicotine and nicotinic receptor modulators .....	227
<i>Nicotine .....</i>	<i>227</i>

<i>Nicotinic receptor modulators</i> .....	228
<i>GTS21</i> .....	230
<i>Ispronicline</i> .....	231
<i>JWB1-84-1</i> .....	231
<b>Neuropeptide/neurotransmitters</b> .....	<b>231</b>
Somatostatin release enhancers .....	231
<b>Glutamate receptor modulators</b> .....	<b>232</b>
Physiology and pharmacology of glutamate receptors .....	232
NMDA receptor ion channel complex .....	232
Metabotropic glutamate receptors .....	233
Glutamate receptor modulators as potential therapeutics for AD .....	234
<i>N2OC</i> .....	235
<i>AMPA modulators</i> .....	235
Glutamate release inhibitors .....	236
<i>INI-0602</i> .....	236
<b>Drugs affecting multiple neurotransmitters</b> .....	<b>236</b>
Ensaculin .....	236
RS-1259 .....	236
Lecozotan .....	236
<b>Vaccines for AD</b> .....	<b>237</b>
Active immunization with A $\beta$ .....	237
<i>AN-1792 vaccine</i> .....	237
<i>Complications in clinical trials with AN-1792</i> .....	238
<i>Effects of A<math>\beta</math> vaccine on the brain</i> .....	238
Strategies to avoid undesirable effect of A $\beta$ vaccination .....	239
Passive immunization in AD .....	240
<i>Passive immunization with MAbs</i> .....	240
<i>Clinical trials of MAbs in AD</i> .....	241
<i>Delivery of the passive antibody directly to the brain</i> .....	242
<i>Systemic injection of MAbs to treat AD</i> .....	243
Combination of A $\beta$ immunotherapy and CD40-CD40L blockade .....	243
Shaping the immune responses elicited against A $\beta$ .....	243
Delivery of AD vaccines .....	244
<i>Gene vaccination</i> .....	244
<i>Modified A<math>\beta</math> nasal vaccine</i> .....	244
<i>Transdermal A<math>\beta</math> vaccination</i> .....	245
Other vaccines for AD .....	245
<i>Nasal vaccination with Proteosome™ adjuvant</i> .....	245
<i>T cell vaccination with glatiramer acetate adjuvant</i> .....	246
Early start of immunotherapy for clearing A $\beta$ plaques .....	246
Reversal of cholinergic dysfunction by anti-A $\beta$ antibody .....	246
Immune modulation via Toll-like receptors to reduce A $\beta$ .....	247
Mechanisms by which A $\beta$ antibodies reduce amyloid accumulation in the brain .....	247
Perspectives on vaccines for AD .....	248
Companies involved in AD vaccines .....	249
<b>Inhibition of amyloid precursor protein aggregation</b> .....	<b>250</b>
Secretase modulators .....	250
<i>Neuroprotection by <math>\alpha</math>-secretase cleaved APP</i> .....	251
<i>Inhibitors of <math>\beta</math>-secretase</i> .....	252
<i>Inhibitors of <math>\gamma</math>-secretase</i> .....	253
Amyloid-derived diffusible ligands .....	254
GABA receptor modulation by etazolate and APP processing .....	255
Depletion of serum amyloid P .....	255
<b>Drugs that inhibit the formation of A<math>\beta</math></b> .....	<b>255</b>
22R-hydroxycholesterol .....	255
Acylaminopyrazole .....	256
Cadmium telluride nanoparticles prevent A $\beta$ fibril formation .....	256
Cannabinoids .....	256
Chelation therapy for AD .....	257
<i>Clioquinol and PBT2</i> .....	257
<i>Copper chelation by FKBP52</i> .....	259
<i>Zinc chelation from amyloid plaques</i> .....	259
<i>Next generation multifunctional chelating agents for AD</i> .....	260
Heparin and its derivatives .....	260
<i>A reassessment of the role of heparin in AD</i> .....	260
<i>Enoxaparin</i> .....	261
<i>Heparan sulfate</i> .....	261
Imatinib mesylate .....	261
Laminin .....	262
Masitinib .....	262
NSAIDs .....	262

<i>Flurbiprofen analogs with Aβ42-lowering action</i> .....	263
<i>Nitric oxide-donating NSAIDs</i> .....	264
<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i> .....	264
Paclitaxel .....	264
Phenserine .....	265
<i>Tolserine</i> .....	265
Platinum-based inhibitors of Aβ .....	266
Retro-inverso peptide inhibitor.....	266
Scyllo-cyclohexanehexol .....	266
Selective serotonin reuptake inhibitor .....	266
Small molecule drug discovery for inhibiting Aβ aggregation.....	267
Trojan-horse approach to prevent build-up of Aβ aggregates.....	267
Ubiquitin C-terminal hydrolase L1 .....	268
<b>Drugs to prevent the formation of NFTs .....</b>	<b>268</b>
<b>Tau suppression.....</b>	<b>268</b>
Anthraquinones .....	269
Anti-tau antibodies.....	269
Tau aggregation inhibitor rember™ .....	269
LMTX® .....	269
Microtubule stabilizers .....	270
<b>ApoE4 as a therapeutic target in AD .....</b>	<b>270</b>
<b>Strategies to prevent deposits and enhance clearance of Aβ .....</b>	<b>270</b>
4,5-dianilinophthalimide for disruption of Aβ <sub>1-42</sub> fibrils.....	271
ABCA1 overexpression to lower amyloid deposits .....	272
ANAVEX 2-73 .....	272
Beta-sheet breakers .....	272
Bexarotene .....	273
Blocking ApoE/Aβ interaction to reduce Aβ plaques .....	273
CD33 inhibitors.....	274
Clearance of Aβ across the blood-brain barrier.....	274
Enhanced PKCε activity promotes clearance of Aβ .....	274
Galantamine-induced Aβ clearance .....	274
Hemopheresis.....	275
Inhibitors of Aβ dehydrogenase .....	275
Intravenous immune globulin .....	275
Monoclonal antibodies for removal of Aβ .....	276
<i>Crenezumab</i> .....	276
<i>Gantenerumab</i> .....	277
<i>Solanezumab</i> .....	277
Nanotechnology for removal of Aβ deposits .....	278
Role of matrix metalloproteinases in clearance of Aβ .....	278
Serum amyloid P component depletion .....	278
Small molecule DAPH for clearance of amyloid.....	279
<b>Companies developing Aβ-directed therapeutics for AD .....</b>	<b>279</b>
<b>Nootropics .....</b>	<b>280</b>
Acetyl-L-carnitine.....	280
Cerebrolysin .....	281
Ergot derivatives.....	281
<i>Lisuride</i> .....	281
<i>Dihydroergocryptine</i> .....	282
<b>Neuroprotective effect drugs not primarily developed for AD .....</b>	<b>282</b>
Antiepileptic drugs .....	283
<i>Lamotrigine</i> .....	283
<i>Levetiracetam</i> .....	283
Antiinflammatory and antimicrobial drugs .....	283
<i>Dapsone</i> .....	283
<i>Antimicrobial drugs against C. pneumoniae</i> .....	284
<i>PPAR-gamma agonists</i> .....	284
Antidiabetic drugs .....	284
<i>Insulin</i> .....	285
<i>Metformin</i> .....	285
<i>Rosiglitazone</i> .....	285
<i>Pioglitazone</i> .....	286
Antihypertensive drugs .....	286
<i>Angiotensin-converting enzyme inhibitors</i> .....	286
<i>Angiotensin receptor blockers</i> .....	286
Bexarotene .....	287
Dimebon .....	287
Drugs acting on estrogen receptors .....	288
<i>Estrogen</i> .....	288
<i>Raloxifene</i> .....	289

Inhibitors of neuroinflammation .....	289
<i>Ceramide</i> .....	289
<i>CSP-1103</i> .....	290
<i>Cyclophosphamide</i> .....	290
<i>Etanercept</i> .....	290
<i>Fingolimod</i> .....	291
<i>Interferon beta-1a</i> .....	291
<i>MW01-5-188WH</i> .....	291
Neurosteroids .....	291
<i>Pregnenolone sulfate</i> .....	292
<i>Dehydroepiandrosterone</i> .....	292
Lithium .....	292
MAO-B inhibitors .....	293
<i>Ladostigil tartrate</i> .....	293
Memoquin .....	294
Methylene blue .....	294
Nilotinib .....	294
Nimodipine.....	295
Rapamycin .....	295
Saracatinib.....	295
Statins.....	296
Testosterone .....	297
Valproic acid.....	297
Future prospects of neuroprotection in AD.....	298
<i>Targeting Cdk5 pathway</i> .....	298
<b>Antioxidants .....</b>	<b>299</b>
Colostrinin .....	299
Curcumin .....	299
Dehydroascorbic acid.....	300
Reservatrol .....	301
Synthetic catalytic scavengers .....	301
<b>Vitamins.....</b>	<b>302</b>
Vitamin E as antioxidant .....	302
Vitamin B for lowering homocysteine .....	302
Folic acid .....	302
<b>Aminopyridazines .....</b>	<b>303</b>
<b>Nanobody-based drugs for AD .....</b>	<b>303</b>
<b>Nitric oxide based therapeutics for AD .....</b>	<b>303</b>
Nitric oxide mimetics .....	303
iNOS inhibitors for AD.....	304
<b>Novel drugs for AD from natural resources .....</b>	<b>304</b>
Berberine chloride .....	305
<i>Centella asiatica</i> .....	305
<i>Ginko biloba</i> .....	306
Huperzine-A .....	307
Hyperforin.....	307
<i>Melissa officinalis</i> .....	308
Nostocarboline derived from cyanobacteria .....	308
<i>Salvia</i> .....	308
<i>Securinega suffruticosa</i> .....	308
<i>Withania somnifera</i> .....	309
ZT-1.....	309
<b>Cholesterol and AD .....</b>	<b>309</b>
ACAT inhibitors .....	310
Role of gene for cholesterol ester transfer protein .....	311
Cholesterol 24S-hydroxylase as a drug target for AD.....	311
Selectively increase of ApoA-I production .....	311
<b>Neurotrophic factors .....</b>	<b>312</b>
Brain derived neurotrophic factor .....	312
Insulin-like growth factor-1 .....	312
Nerve growth factor .....	313
Neotrofin (AIT-082).....	314
Limitations of the use of NTFs for AD .....	314
<b>Role of serotonin modulators in AD .....</b>	<b>314</b>
Xaliproden .....	314
5-HT <sub>1A</sub> receptor antagonists .....	315
5-HT <sub>6</sub> antagonists .....	315
5-HT <sub>4</sub> receptor agonists.....	315
<i>PRX-03140</i> .....	316
<i>Donecopride</i> .....	316
<b>Restoration of factors deficient in the aging brain .....</b>	<b>317</b>

Reversal of cognitive impairment in aging by activation of creb protein .....	317
Reversal of cognitive impairment in aging by GDF11 protein .....	317
Restoration of repressor element 1-silencing transcription factor.....	317
<b>Cell therapy for AD.....</b>	<b>318</b>
Stem cell transplantation for AD .....	318
<i>Potential benefits of grafting NSCs in AD.....</i>	<i>318</i>
<i>NSCs improve cognition in AD via BDNF.....</i>	<i>319</i>
<i>Drugs for enhancing neuronal differentiation of implanted NSCs.....</i>	<i>319</i>
Choroid plexus epithelial cells for AD .....	319
Implantation of encapsulated cells for delivering NGF .....	320
<b>Gene therapy for AD .....</b>	<b>320</b>
ApoE gene therapy.....	320
<i>APPsa gene transfer for rescuing synaptic failure in AD.....</i>	<i>320</i>
FGF2 gene transfer in AD.....	321
Humanin gene therapy .....	321
Neprilysin gene therapy .....	321
NGF gene therapy .....	322
Targeting plasminogen activator inhibitor type-1 gene.....	323
<b>Antisense approaches to AD .....</b>	<b>323</b>
Antisense PNA in AD.....	323
Antisense tau in AD.....	324
<b>RNAi approaches to AD .....</b>	<b>324</b>
<b>Combined therapeutic approaches to AD .....</b>	<b>325</b>
<b>Drug delivery for Alzheimer disease .....</b>	<b>325</b>
Delivery of biologicals across the BBB .....	326
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	326
Nanoparticle-based drug delivery for Alzheimer's disease.....	327
Transdermal drug delivery in Alzheimer's disease.....	328
<i>Transdermal rivastigmine.....</i>	<i>328</i>
Intranasal delivery of therapeutics for AD .....	328
<i>Intranasal delivery of tacrine.....</i>	<i>328</i>
<i>Intranasal delivery of nerve growth factor to the brain.....</i>	<i>328</i>
Circadian rhythms and timing of cholinesterase inhibitor therapy .....	329
<b>Clinical trials for AD .....</b>	<b>329</b>
Drugs for AD that were discontinued in clinical trials.....	337
Concluding remarks on clinical trials of AD .....	341
<b>Drug discovery for AD .....</b>	<b>342</b>
Drugs acting on signaling pathways.....	342
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1 .....</i>	<i>342</i>
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD .....</i>	<i>343</i>
<i>Inhibition of the CD40 signaling pathway .....</i>	<i>343</i>
<i>JNK pathway as a target .....</i>	<i>344</i>
<i>Mitogen-activated protein kinase pathway as target .....</i>	<i>344</i>
<i>Protein kinase C activators .....</i>	<i>344</i>
Electrophysiological detection of drug target for neuroprotection in early AD .....	345
Genomics-based drug discovery.....	345
High through screening for AD drug candidates .....	345
New chemical entities for AD by combining galantamine and memantine .....	346
Novel rivastigmine-hydroxycinnamic acid hybrids for AD.....	346
Novels targets/receptors for AD drug discovery .....	346
<i>Activation of cerebral Rho GTPases.....</i>	<i>346</i>
<i>Activators of insulin-degrading enzyme.....</i>	<i>347</i>
<i>Blockade of TGF-<math>\beta</math>-Smad2/3 signaling in peripheral macrophages .....</i>	<i>347</i>
<i>Calcium channel blockers .....</i>	<i>347</i>
<i>Calpain inhibitors .....</i>	<i>348</i>
<i>Casein kinase 1.....</i>	<i>348</i>
<i>Cyclin-dependent kinase-5 .....</i>	<i>348</i>
<i>Drugs against arginine deprivation and immune suppression in AD.....</i>	<i>349</i>
<i>Heat shock protein 90 inhibitors.....</i>	<i>349</i>
<i>Histone deacetylase inhibitors.....</i>	<i>350</i>
<i>Inhibition of PDK1 to slow progression of both AD and prion disease .....</i>	<i>350</i>
<i>Melatonin .....</i>	<i>350</i>
<i>Neurotrophic compound J147 .....</i>	<i>351</i>
<i>NF-<math>\kappa</math>B inhibitors .....</i>	<i>351</i>
<i>Kinases and phosphatases as targets for AD therapeutics.....</i>	<i>351</i>
<i>Neutral sphingomyelinase inhibitors .....</i>	<i>352</i>
<i>Phosphodiesterase inhibitors .....</i>	<i>352</i>
<i>Pin 1 as a target in AD.....</i>	<i>353</i>
<i>Protein phosphatase 5 as a neuroprotective in AD.....</i>	<i>353</i>
<i>Single drugs for multiple targets in AD.....</i>	<i>354</i>
<i>Src homology-containing protein-1 inhibitors.....</i>	<i>354</i>

<i>Targeting GABAergic system</i> .....	354
<i>TSPO ligands</i> .....	354
Proteomics and drug discovery for AD.....	355
Small molecule compounds binding to neurotrophin receptor p75NTR.....	356
<i>Targeting Vav in tyrosine kinase signaling pathway</i> .....	357
<i>LM11A-31 as p75NTR ligand</i> .....	357
<b>Pharmacogenomics of Alzheimer disease</b> .....	<b>358</b>
Biomarkers and companion diagnostics for AD.....	358
Personalized therapy of AD.....	358
Genotyping and AD therapeutics.....	359
<b>Regulatory aspects of drug development for AD</b> .....	<b>360</b>
EMA guidelines for drug development for AD.....	360
FDA guidelines for drug development for AD.....	360
<b>Concluding remarks and future of AD research</b> .....	<b>361</b>
Future for AD therapeutics.....	362
<b>6. Markets &amp; Finances of AD Care</b> .....	<b>365</b>
<b>Introduction</b> .....	<b>365</b>
<b>Pharmacoeconomics of treatment of AD</b> .....	<b>365</b>
Quality of Life in relation to economics of AD.....	365
Costs associated with Alzheimer disease.....	365
Pharmacoeconomics of donepezil.....	366
Pharmacoeconomics studies using rivastigmine.....	366
Pharmacoeconomics studies using galantamine.....	367
Pharmacoeconomics studies using memantine.....	367
<b>Patterns of AD care in major markets</b> .....	<b>367</b>
Care of AD patients in the US.....	368
<i>Cost of care</i> .....	368
<i>Medicare and AD</i> .....	369
<i>Patterns of practice in AD care</i> .....	370
<i>Opinions of physicians' organizations on drugs for dementia</i> .....	370
Care of AD patients in the UK.....	371
<i>Cost of care</i> .....	371
<i>Patterns of practice in AD care</i> .....	371
<i>NICE recommendations to NHS</i> .....	372
Care of AD patients in Germany.....	373
Care of AD patients in France.....	374
Care of AD patients in Italy.....	374
Care of AD patients in Spain.....	374
Care of AD patients in Japan.....	375
<b>Markets for AD diagnostics</b> .....	<b>375</b>
<b>Markets for AD therapeutics</b> .....	<b>375</b>
Geographical markets for AD.....	375
Markets for currently approved drugs for AD.....	376
Markets for generic AD drugs.....	377
Statins.....	377
Future growth of AD market.....	377
<b>Limitations of AD drug development by the biotechnology industry</b> .....	<b>378</b>
<b>Unmet needs in the management of AD</b> .....	<b>379</b>
<b>Drivers of AD markets</b> .....	<b>380</b>
Increase of the aged populations.....	380
Increase in the number of approved drugs for AD.....	380
Limitations of the current therapies.....	380
Improvements in diagnosis.....	381
Increasing awareness of the disease.....	381
<b>7. Companies</b> .....	<b>383</b>
<b>Introduction</b> .....	<b>383</b>
<b>Profiles of companies</b> .....	<b>383</b>
<b>Collaborations</b> .....	<b>508</b>
<b>8. References</b> .....	<b>513</b>

## Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease.....	19
Table 1-2: Clinical features of Alzheimer disease.....	20
Table 1-3: Non-Alzheimer dementias.....	25
Table 1-4: A guide to evaluation for MCI due to AD.....	29
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease.....	30

Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease .....	31
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders .....	40
Table 1-8: Risk factors for Alzheimer's disease .....	76
Table 1-9: Genes linked to AD .....	92
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD .....	108
Table 2-1: Classification of methods of diagnosis of Alzheimer disease .....	112
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease .....	113
Table 2-3: Available molecular diagnostic tests for Alzheimer disease .....	121
Table 2-4: Biomarkers of AD in blood and CSF .....	123
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease .....	125
Table 2-6: Role of biomarkers in diagnosis of AD dementia .....	161
Table 2-7: Companies involved in the diagnosis/monitoring of Alzheimer disease .....	163
Table 3-1: Classification of treatments for Alzheimer disease .....	166
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease .....	167
Table 3-3: Categories of neuroprotective agents for Alzheimer disease .....	175
Table 3-4: Strategies for prevention of Alzheimer disease .....	191
Table 3-5: Guidelines for the treatment of dementia .....	200
Table 4-1: Transgenic mouse models of Alzheimer disease .....	204
Table 4-2: Correlation of studies in animal models with human clinical trials .....	211
Table 5-1: Classification of therapies in development for Alzheimer disease .....	221
Table 5-2: Drugs for AD targeting nACh receptors .....	230
Table 5-3: Ionotropic glutamate receptors .....	232
Table 5-4: Classification of mGluRs .....	232
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD .....	234
Table 5-6: Companies involved in developing vaccines for AD .....	249
Table 5-7: Preclinical studies of secretase modulators .....	250
Table 5-8: Secretase modulators in clinical trials .....	251
Table 5-9: Companies developing A $\beta$ -directed therapeutics for AD .....	279
Table 5-10: Innovative neuroprotective approaches for Alzheimer disease .....	282
Table 5-11: Herbal therapies for AD .....	304
Table 5-12: Novel drug delivery methods for Alzheimer disease therapies .....	325
Table 5-13: Clinical trials in Alzheimer disease .....	331
Table 5-14: Discontinued, failed or inconclusive clinical trials of Alzheimer disease .....	338
Table 6-1: Direct and indirect costs associated with Alzheimer disease .....	368
Table 6-2: Prevalence of AD in major markets 2017-2027 .....	375
Table 6-3: AD market values from 2017-2027 in major world markets .....	376
Table 6-4: Markets for currently approved AD drugs 2017-2027 .....	376
Table 6-5: Potential markets for drugs in development 2017-2027 .....	377
Table 6-6: Limitations of AD drug development by the biotechnology industry .....	378
Table 6-7: Factors that drive AD markets .....	380
Table 7-1: Major players in Alzheimer's disease therapeutics .....	383
Table 7-2: Collaborations relevant to Alzheimer disease .....	508

## Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050. ....	32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020 .....	33
Figure 1-3: Prevalence of different types of dementia .....	34
Figure 1-4: Structure of tau in a brain with AD .....	38
Figure 1-5: A $\beta$ deposits in the brain .....	45
Figure 1-6: Major pathological features of AD .....	46
Figure 1-7: Mechanisms of A $\beta$ clearance .....	46
Figure 1-8: Pathways for A $\beta$ -induced nerve cell death .....	51
Figure 1-9: Insulin signaling in Alzheimer disease and diabetes .....	63
Figure 1-10: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease .....	69
Figure 1-11: Oxidative stress and Alzheimer disease .....	71
Figure 1-12: Role of proteasome inhibition in A $\beta$ generation and neurodegeneration .....	75
Figure 1-13: Cholesterol-related pathways to AD .....	77
Figure 1-14: Pathomechanism of AD .....	88
Figure 3-1: Metabolism of acetylcholine .....	168
Figure 3-2: Neuroprotective effective of galantamine in AD .....	172
Figure 3-3: Strategies for the management of Alzheimer disease .....	202
Figure 5-1: Activation of $\alpha$ 7 nicotinic acetylcholine receptors .....	229
Figure 5-2: NMDA receptor ion channel complex .....	233
Figure 5-3: Neurotoxicity due to misfolding of A $\beta$ 1-42 .....	271
Figure 5-4: Interactions of players in clinical trials of Alzheimer disease in the USA .....	330
Figure 5-5: Role of proteomics in drug discovery/development for Alzheimer disease .....	356
Figure 5-6: FDA industry interaction during drug development for AD .....	361
Figure 5-7: FDA's accelerated approval pathway in early Alzheimer disease .....	363
Figure 6-1: Unmet needs in the management of Alzheimer disease .....	379